Antiphospholipid antibody associated thrombosis: A consensus for treatment?

Abstract

The results of several studies have demonstrated that antiphospholipid antibodies (APLA) are associated with an increased risk of both venous and arterial thrombosis. Additional work has suggested that patients with antiphospholipid antibody-associated thrombosis are at a markedly increased risk for recurrent thrombotic disease, and several investigators have suggested that such patients should receive high-intensity anticoagulant therapy for an indefinite period of time for prophylaxis of recurrent thrombotic events. However, the majority of these studies are retrospective and include highly-selected patient populations, and the potential morbidity of long-term, intensive warfarin therapy has not been fully considered. In this article, studies concerning the incidence and prevention of recurrent thrombosis in patients with antiphospholipid antibodies are reviewed. I will also present the results of a survey in which opinions concerning selected issues in prophylactic anticoagulant therapy of patients with antiphospholipid antibody-associated venous thrombosis were obtained from prominent clinicians with expertise in this area. The results of the survey demonstrate that opinions concerning this issue vary widely, and emphasize the need for additional prospective studies examining the utility of specific anticoagulant regimens in the prophylaxis of recurrent thromboembolism in patients with antiphospholipid antibodies.

Keywords

antiphospholipid antibodies lupus anticoagulant anticardiolipin antibodies thrombo sis warfarin

Get full access to this article

View all access options for this article.

References

Bowie Ejw , Thompson JH , Pascuzzi CA , Owen CA Thrombosis in systemic lupus erythematosus despite circulating anticoagulants . J Lab Clin Med 1963; 62: 416-430.

Feinstein DI , Rapaport SI Acquired inhibitors of blood coagulation. In Spaet TH (ed). Progress in Hemostasis and Thrombosis. Grune Stratton: New York, 1972; 75-87.

Boey ML et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Lancet 1983; 287: 1021-1023.

Elias M. , Eldor A. Thromboembolism in patients with the 'lupus'-type circulating anticoagulant . Arch Int Med 1984; 144: 510-515.

Mueh JR , Herbst KD , Rapaport SI Thrombosis in patients with the lupus anticoagulant. Ann Int Med 1980; 92: 156-159.

Hughes Grv. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant . Br Med J 1983; 289: 1088-1089.

Harris EN et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211-1214.

Harris EN et al. Thrombosis, recurrent fetal loss and thrombocytopenia: Predictive value of the anticardiolipin antibody test. Arch Int Med 1986; 146: 2153-2156.

Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): First report from the Italian registry. Haematologica 1993; 78: 313-318.

10.

Ginsburg KS et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Int Med 1992; 117: 997-1002.

11.

Hamsten A. et al. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events. Lancet 1986; ii: 113-115.

12.

Morton KE et al. Coronary artery bypass graft failure—an autoimmune phenomenon ?. Lancet 1986; ii: 1353-1356.

13.

Levine SR , Brey RL , Joseph Clm , Havstad S. Antiphospholipid Antibodies in Stroke Study Group: Risk of recurrent thromembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies . Stroke 1992; 23 (suppl. 1): 129-132.

14.

Asherson RA et al. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis 1985 ; 44: 823-825.

15.

Asherson RA , Baguley E. , Pal C. , Hughes Grv. Antiphospholipid syndrome: five year follow up. Ann Rheum Dis 1991; 50: 805-810.

16.

Derksen RHWM, De Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment . Ann Rheum Dis 1993; 52: 689-692.

17.

Rosove MH , Brewer Pmc. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-308.

18.

Khamashta MA et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.

19.

Nordström M. , Lindblad B. , Bergqvist D. , Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population . J Int Med 1992; 232: 155-160.

20.

Hull R. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.

21.

Hull R. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.

22.

Schulman S. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism . N Engl J Med 1995; 332: 1661-1665.

23.

Landefeld CS , Rosenblatt MW , Goldman L. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-159.

24.

Hull R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-1681.

25.

Landefeld CS , Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.

26.

van der Meer Fjm , Rosendaal FR , Vandenbroucke JP , Briet E. Bleeding complications in oral anticoagulant patients. Arch Int Med 1993; 153: 1557-1562.

27.

Hylek EM , Singer DE Risk factors for intracranial hemorrhage in outpatients taking warfarin . Ann Int Med 1994; 120: 897-902.

28.

Fihn SD et al. Risk factors for complications of chronic anticoagulation. Ann Int Med 1993; 118: 511-520.

29.

Levine MN , Hirsh J. , Landefeld S. , Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102 (suppl.): 352S-363S.

30.

Ginsberg JS et al. Antiphosphilipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.

31.

Kmic S. et al. Clinical, laboratory and treatment factors influencing recurrent thrombosis in the antiphospholipid syndrome. (submitted for publication).

32.

Asherson RA The catastrophic antiphospholipid syndrome . J Rheum 1992; 19: 508-512.

33.

Ferro D. , Quintarelli C. , Valesini G. , Violi F. Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus. Blood 1994 ; 83: 304.

34.

Ginsberg JS et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: Evidence for a prothrombotic state. Blood 1993; 81: 2958-2963.

35.

Galli M. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1554-1559.

36.

McNeil HP , Simpson RJ , Chesterman CN , Krillis SA Antiphosphilipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4125.

37.

Matsuura E. et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990 ; 335: 177-178.

38.

Shi W. et al. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990 ; 20: 231-236.

39.

Barbui T. , Finazzi G. Clinical trials on antiphospholipid syndrome: What is being done and what is needed?. Lupus 1994; 3: 303-307.